Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Journal of Clinical Oncology · 20.07.2023 · 41 (21) · 3663-3669
DOI: 10.1200/jco.22.02760 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.07.2023. Verfasst von Leonard B Saltz und 12 weiteren Autor:innen. Beteiligte Einrichtung: From the Memorial Sloan-Kettering Cancer Center, New York, NY; University of Sydney and Sydney Cancer Centre, Sydney, Australia; Hospital Clínico San…. Die Arbeit wurde bisher 33-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC). Patients and Methods Patients with MCRC were randomly assigned, in a 2 × 2 factorial design, to XELOX versus FOLFOX-4, and then to bevacizumab versus placebo. The primary end point was progression-free survival (PFS).
Results
A total of 1,401 patients were randomly assigned in this 2 × 2 analysis. Median progression-free survival (PFS) was 9.4 months in the bevacizumab group and 8.0 months in the placebo group (hazard ratio [HR], 0.83; 97.5% CI, 0.72 to 0.95; P = .0023). Median overall survival was 21.3 months in the bevacizumab group and 19.9 months in the placebo group (HR, 0.89; 97.5% CI, 0.76 to 1.03; P = .077). Response rates were similar in both arms. Analysis of treatment withdrawals showed that, despite protocol allowance of treatment continuation until disease progression, only 29% and 47% of bevacizumab and placebo recipients, respectively, were treated until progression. The toxicity profile of bevacizumab was consistent with that documented in previous trials.
Conclusion
The addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS in this first-line trial in patients with MCRC. Overall survival differences did not reach statistical significance, and response rate was not improved by the addition of bevacizumab. Treatment continuation until disease progression may be necessary in order to optimize the contribution of bevacizumab to therapy.
Autor:innen und Institutionen
- From the Memorial Sloan-Kettering Cancer Center, New York, NY; University of Sydney and Sydney Cancer Centre, Sydney, Australia; Hospital Clínico San Carlos, Madrid; Hospital Marques de Valdecilla, Santander, Spain; Vie…
Zitieren
APA
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T. S., Rivera, F., Couture, F., Sirzén, F., & Cassidy, J. (2023). Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology, 41(21), 3663-3669. https://doi.org/10.1200/jco.22.02760
Vancouver
Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology. 2023;41(21):3663-3669. doi:10.1200/jco.22.02760
BibTeX
@article{Saltz2023,
author = {Saltz, Leonard B and Clarke, Stephen and Díaz-Rubio, Eduardo and Scheithauer, Werner and Figer, Arie and Wong, Ralph and Koski, Sheryl and Lichinitser, Mikhail and Yang, Tsai-Shen and Rivera, Fernando and Couture, Felix and Sirzén, Florin and Cassidy, Jim},
title = {Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {21},
pages = {3663--3669},
doi = {10.1200/jco.22.02760}
}
EUVIMED